Impact on Revenue and Business Continuity from the Termination of Specific Licensing Agreements or Decisions by Partners
First written in FY2024. 1 of 2 entries say "Materialised", first in FY2025. Latest entry: FY2025.
Chordia Therapeutics moved to the "Worse" side of this theme in 2025.
The whole theme swung hardest in 2021: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Materialised".
- FY2025MaterialisedAnnual report
「On 28 April 2025, we received notification from Ono Pharmaceutical that it would discontinue the clinical trial for strategic reasons. As the license agreement with Ono Pharmaceutical has ended, we now hold the worldwide exclusive rights to research, develop, manufacture and commercialize the product.」
Following the partner's strategic decision, the CTX-177 clinical trial was discontinued and the license agreement was terminated, with the rights reverting to the company. - FY2024First statedAnnual report
「Revenue under the CTX-177 license agreement includes milestones linked to development progress. If development is delayed, suspended or discontinued due to factors beyond our control, such as a change in the partner's management policy, or if the partner is unable to fulfill the contractual terms or comply with applicable regulations, the partnership agreement may be cancelled or terminated, or its terms may be changed, potentially having a material impact on our business performance and financial position.」
The risk was disclosed that revenue dependent on partnership agreements, including up to ¥49.6 billion in milestones under the CTX-177 agreement, could be affected by contract termination, changes to terms or suspension of development.